The changes of plasma and alveolar inflammatory mediators levels during cardiac surgery under cardiopulmonary bypass

The changes of plasma and alveolar inflammatory mediators levels during cardiac surgery under cardiopulmonary bypass - The changes of plasma and alveolar inflammatory mediators levels during cardiac surgery under cardiopulmonary bypass

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012438

Enrollment

Registered

2013-11-29

Start date

2012-11-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac surgery patients

Interventions

remifentanil administration 0.25 microg/kg/hr i.v. intraoperatively dexmedetomidine administration 0.5 microg/kg/hr i.v. intraoperatively control group (received the same volume of saline)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 18 years of age or older who underwent elective cardiac surgery with cardiopulmonary bypass

Exclusion criteria

Exclusion criteria: previous heart surgery, infection disease, chronic administration of an anti-inflammatory treatment

Design outcomes

Primary

Measure	Time frame
plasma and alveolar inflammatory mediators (HMGB1 and IL-6) level, liver function, renal function, myocardial function	—

Countries

Japan

Contacts

Public ContactTakashi Kawasaki

University of Occupational and Environmental Health Department of Anesthesiology

takasi-k@med.uoeh-u.ac.jp093-691-7265

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026